Agrawal R, Majeed M, Attar BM, et al. - In patients with an inadequate response to ursodeoxycholic acid (UDCA), the first and most widely used medication for primary biliary cholangitis (PBC) has shown to improve biochemical markers and improve transplant-free survival, researchers tested the safety and effectiveness of using both UDCA and bezafibrate, a hypolipidemic fibrate currently approved for PBC treatment in France. Ten trials have been evaluated with a total of 369 patients. According to findings, combined therapy with UDCA and bezafibrate is superior to UDCA alone in UDCA non-responders in terms of reducing markers of liver biochemistry, with no important rise in side effects (pruritus, myalgia, fatigue or elevation of creatinine kinase levels) in PBC patients.